Pipeline PotentialAZN has 5 game-changing Phase III reads for key assets with a total sales potential of around $20 billion.
Revenue And ReratingAZN's new mid-term guide implies 30E revenues 20% above consensus and 30E EBIT at the bottom end of margin guide 10% above consensus.
Sales GrowthSolid key sales drivers (Imfinzi +14%, Farxiga +25%, Fasenra +4%), with a notable acceleration in oral oncology franchises (Tagrisso +6%, Lynparza +5%, Calquence +14%).